Screener
Twist Bioscience Corporation TWST Reportable Segment — Research and development expenses
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Twist Bioscience Corporation in its filing.
Tagged under the XBRL concept twst:ResearchAndDevelopmentExpenseExcludingDepreciationAmortizationAndShareBasedCompensationExpense.
The source filing: Twist Bioscience Corporation’s 10-Q, filed May 4, 2026.
- Filed
- May 4, 2026, 4:28 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001581280-26-000040
| (in thousands) | Three months ended March 31, 2026 | Three months ended March 31, 2025 | Six months ended March 31, 2026 | Six months ended March 31, 2025 |
|---|---|---|---|---|
| Revenues | $110,715 | $92,793 | $214,413 | $181,506 |
| Costs and expenses: | ||||
| Cost of revenues[1] | $47,402 | $40,373 | $91,408 | $80,744 |
| Research and development expenses[1] | 17,366 | 19,952 | 32,712 | 38,078 |
| Selling, general and administrative expenses[1] | 59,255 | 47,298 | 117,034 | 93,786 |
| Litigation settlement costs, net of recoveries | 7,205 | — | 7,205 | — |
| Depreciation and amortization | 6,414 | 6,402 | 12,608 | 12,784 |
| Stock-based compensation expense | 18,936 | 20,328 | 32,209 | 32,319 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Twist Bioscience Corporation's reportable segment — research and development expenses?
- Twist Bioscience Corporation (TWST) reported reportable segment — research and development expenses of $17.37M in Q1 2026.
- How has Twist Bioscience Corporation's reportable segment — research and development expenses changed year-over-year?
- Twist Bioscience Corporation's reportable segment — research and development expenses decreased by 13.0% year-over-year, from $19.95M to $17.37M.
- What does reportable segment — research and development expenses mean?
- Captures the costs incurred by the reportable segment to discover and develop new technologies, products, or processes. This investment is critical for maintaining long-term competitive advantage and innovation within the company's specific industry.
Ask your AI about Twist Bioscience Corporation's reportable segment — research and development expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude